The global dipeptidyl peptidase IV inhibitors market was valued at US$ XX Mn in 2018 and increasing at a prominent growth rate over the forecast years due to increase in the prevalence of diabetes around the globe. For instance, according to International Diabetes Foundation 2017, approximately 425 Mn adults were living with diabetes and this will expected to reach 629 Mn by 2045. Moreover, grow in geriatric population, increase in the R&D expenditure for the development of newer drugs, ... Read more